Retrospective analysis of DDAVP response in patients with von Willebrand Disease

Retrospective analysis of DDAVP response in patients with von Willebrand Disease - DDAVP_IIT

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00039129

Enrollment

150

Registered

2026-01-30

Start date

2026-02-16

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

D66

Interventions

Group 1: Retrospective analysis of all patients with von Willebrand Disease type 1, 2A or 2M and DDAVP-test in period 2015 to 2025

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: • Patients. with confirmed von Willebrand Disease type 1, 2A or 2 M (according to ISTH criteria) • conduction of DDAVP test

Exclusion criteria

Exclusion criteria: • Patients without confirmed von Willebrand Disease and patients with von Willebrand Disease type 2B, 3 • Patients with seizures, cardiovascular diseases, hypertension, or taking diuretics • Patienten with maligne, lymphoproliferative and autoimmunologic diseases and patients undergoing valproate therapy • Patients with current pregnancy

Design outcomes

Primary

Measure	Time frame
Laboratory parameters: VWD diagnostics at time points 0, 1, 2, 3 h post DDAVP dose •VWF antigen •VWF activity •Factor VIII activity •VWF activity/VWF antigen ratio	—

Secondary

Measure	Time frame
Laborparameter: 0, 1, 2, 3 h post DDAVP dose • VWF collagen binding activity •. VWF-Multimer-Analyse • VWF:FVIIIB, falls vorhanden • RIPA (Ristocetin-induced platelet aggregation) Demographics: • age at time of sample collection • sec • ABO blood group • body weight/BMI • ethnicity Clinical anamnesis • ISTH-BAT Bleeding Score • VWS Type Classification • Detailed bleeding history: epistaxis, menorrhagia, tooth extractions, bleeding complications in surgical procedures, postoperative • Family history: autosomal dominant or recessive inheritance patterns • Comorbidities: underlying conditions that may cause acquired VWD • Medications: anticoagulants, antiplatelet agents • Contraceptives	—

Measure

Time frame

Laborparameter: 0, 1, 2, 3 h post DDAVP dose • VWF collagen binding activity •. VWF-Multimer-Analyse • VWF:FVIIIB, falls vorhanden • RIPA (Ristocetin-induced platelet aggregation) Demographics: • age at time of sample collection • sec • ABO blood group • body weight/BMI • ethnicity Clinical anamnesis • ISTH-BAT Bleeding Score • VWS Type Classification • Detailed bleeding history: epistaxis, menorrhagia, tooth extractions, bleeding complications in surgical procedures, postoperative • Family history: autosomal dominant or recessive inheritance patterns • Comorbidities: underlying conditions that may cause acquired VWD • Medications: anticoagulants, antiplatelet agents • Contraceptives

—

Countries

Germany

Contacts

Public ContactWolfgang Miesbach

Goethe Universität Frankfurt, Hämophiliezentrum/Hämostaseologie, Universitätsklinikum

Wolfgang.miesbach@unimedizin-ffm.de+496963015051

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026